URGN
$17.62-0.97 (-5.22%)
UroGen Pharma Ltd.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyeloca...
Recent News
How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities
UroGen Pharma’s fair value estimate holds at US$35.63, with recent model tweaks leaving the price target itself unchanged. Analysts are using recent moves in other healthcare names, where cost pressures, technical updates, and financing choices affected targets, as a reference point for factors that could eventually influence UroGen’s valuation story. As you read on, you will see how bullish and bearish voices are interpreting these signals and what to watch to stay on top of the evolving...
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish
This clinical-stage biotech develops therapies for CML, NASH, and obesity.
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push
UroGen Pharma (NasdaqGM:URGN) reported new Phase 3 ENVISION trial analyses for ZUSDURI in recurrent low grade intermediate risk non muscle invasive bladder cancer, showing strong efficacy across risk groups. The company highlighted high complete response rates and durable benefit in a patient population with limited treatment options. UroGen also secured an expanded US$250 million non dilutive term loan with a fixed interest rate and no financial covenants to support clinical and commercial...